Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lifitegrast/Perfluorohexyloctane Fixed Dose Combination · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | ACTIVE_COMPARATOR | - |
| Arm 4 | PLACEBO_COMPARATOR | - |
| Arm 5 | PLACEBO_COMPARATOR | - |
| Arm 6 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Lifitegrast/Perfluorohexyloctane Fixed Dose Combination | DRUG | Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks |
| Lifitegrast | DRUG | Topical ocular drop of lifitegrast administered for 4 weeks |
| Perfluorohexyloctane | DRUG | Topical ocular drop of perfluorohexyloctane administered for 4 weeks |
| Vehicle | DRUG | Topical ocular drop with no active ingredients administered for 4 weeks |
Inclusion Criteria: This study will include subjects who meet all of the following inclusion criteria: * Voluntarily provide written informed consent * ≥18 years of age * Subject-reported history of DED OU for at least 6 months * Same eye satisfies the criteria for dry eye signs at both screening ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 1 | N/A | Undisclosed |
| Harrow, Inc. | HROW | 1 | - | Undisclosed |